Mycenax Biotech Asset Resilience Ratio
Mycenax Biotech asset resilience ratio. Mycenax Biotech (4726) has an Asset Resilience Ratio of 0.04% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Mycenax Biotech (4726) liquidity interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Mycenax Biotech (2017–2024)
Asset resilience ratio of Mycenax Biotech from 2017 to 2024. This chart shows how Mycenax Biotech's Asset Resilience Ratio has changed over time. Read 4726 total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Mycenax Biotech's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 4726 total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$1.20 Million | 0.04% |
| Total Liquid Assets | NT$1.20 Million | 0.04% |
Asset Resilience Insights
- Limited Liquidity: Mycenax Biotech maintains only 0.04% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Mycenax Biotech Industry Peers by Asset Resilience Ratio
Compare Mycenax Biotech's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Mycenax Biotech Asset Resilience Ratio by Year (2017–2024)
Mycenax Biotech asset resilience ratio by year from 2017 to 2024. The table below shows the annual Asset Resilience Ratio data for Mycenax Biotech.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.25% | NT$8.50 Million ≈ $267.80K |
NT$3.37 Billion ≈ $106.12 Million |
-3.72pp |
| 2023-12-31 | 3.97% | NT$149.62 Million ≈ $4.71 Million |
NT$3.77 Billion ≈ $118.79 Million |
+3.58pp |
| 2022-12-31 | 0.39% | NT$17.32 Million ≈ $545.55K |
NT$4.45 Billion ≈ $140.29 Million |
+0.12pp |
| 2021-12-31 | 0.27% | NT$8.50 Million ≈ $267.80K |
NT$3.14 Billion ≈ $98.90 Million |
+0.20pp |
| 2020-12-31 | 0.07% | NT$1.20 Million ≈ $37.81K |
NT$1.75 Billion ≈ $55.22 Million |
-5.95pp |
| 2019-12-31 | 6.02% | NT$84.76 Million ≈ $2.67 Million |
NT$1.41 Billion ≈ $44.36 Million |
-2.79pp |
| 2018-12-31 | 8.81% | NT$98.60 Million ≈ $3.11 Million |
NT$1.12 Billion ≈ $35.25 Million |
-13.48pp |
| 2017-12-31 | 22.30% | NT$292.69 Million ≈ $9.22 Million |
NT$1.31 Billion ≈ $41.36 Million |
-- |
About Mycenax Biotech
Mycenax Biotech Inc. provides biopharmaceutical services and solutions for drug development and production in Taiwan. The company's services include program evaluation/confirmation, cell line development and construction, process development technology platforms, drug characterization analysis, establishment of testing methods, and PIC/S GMP drug production. It offers plasmid DNA, antibody-drug c… Read more